Literature DB >> 22753476

α4βδ GABA(A) receptors are high-affinity targets for γ-hydroxybutyric acid (GHB).

Nathan Absalom1, Laura F Eghorn, Inge S Villumsen, Nasiara Karim, Tina Bay, Jesper V Olsen, Gitte M Knudsen, Hans Bräuner-Osborne, Bente Frølund, Rasmus P Clausen, Mary Chebib, Petrine Wellendorph.   

Abstract

γ-Hydroxybutyric acid (GHB) binding to brain-specific high-affinity sites is well-established and proposed to explain both physiological and pharmacological actions. However, the mechanistic links between these lines of data are unknown. To identify molecular targets for specific GHB high-affinity binding, we undertook photolinking studies combined with proteomic analyses and identified several GABA(A) receptor subunits as possible candidates. A subsequent functional screening of various recombinant GABA(A) receptors in Xenopus laevis oocytes using the two-electrode voltage clamp technique showed GHB to be a partial agonist at αβδ- but not αβγ-receptors, proving that the δ-subunit is essential for potency and efficacy. GHB showed preference for α4 over α(1,2,6)-subunits and preferably activated α4β1δ (EC(50) = 140 nM) over α4β(2/3)δ (EC(50) = 8.41/1.03 mM). Introduction of a mutation, α4F71L, in α4β1(δ)-receptors completely abolished GHB but not GABA function, indicating nonidentical binding sites. Radioligand binding studies using the specific GHB radioligand [(3)H](E,RS)-(6,7,8,9-tetrahydro-5-hydroxy-5H-benzocyclohept-6-ylidene)acetic acid showed a 39% reduction (P = 0.0056) in the number of binding sites in α4 KO brain tissue compared with WT controls, corroborating the direct involvement of the α4-subunit in high-affinity GHB binding. Our data link specific GHB forebrain binding sites with α4-containing GABA(A) receptors and postulate a role for extrasynaptic α4δ-containing GABA(A) receptors in GHB pharmacology and physiology. This finding will aid in elucidating the molecular mechanisms behind the proposed function of GHB as a neurotransmitter and its unique therapeutic effects in narcolepsy and alcoholism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22753476      PMCID: PMC3421209          DOI: 10.1073/pnas.1204376109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

1.  Gamma-hydroxybutyric acid: an endogenous neuromodulator with abuse potential?

Authors:  R Bernasconi; P Mathivet; S Bischoff; C Marescaux
Journal:  Trends Pharmacol Sci       Date:  1999-04       Impact factor: 14.819

2.  Low nanomolar GABA effects at extrasynaptic α4β1/β3δ GABA(A) receptor subtypes indicate a different binding mode for GABA at these receptors.

Authors:  Nasiara Karim; Petrine Wellendorph; Nathan Absalom; Line Haunstrup Bang; Marianne Lerbech Jensen; Maja Michelle Hansen; Ho Joon Lee; Graham A R Johnston; Jane R Hanrahan; Mary Chebib
Journal:  Biochem Pharmacol       Date:  2012-05-29       Impact factor: 5.858

3.  γ-Hydroxybutyrate and the GABAergic footprint: a metabolomic approach to unpicking the actions of GHB.

Authors:  Fatima A Nasrallah; Anthony D Maher; Jane R Hanrahan; Vladimir J Balcar; Caroline D Rae
Journal:  J Neurochem       Date:  2010-10       Impact factor: 5.372

4.  Molecular basis for the high THIP/gaboxadol sensitivity of extrasynaptic GABA(A) receptors.

Authors:  Pratap Meera; Martin Wallner; Thomas S Otis
Journal:  J Neurophysiol       Date:  2011-07-27       Impact factor: 2.714

5.  GABAA receptor alpha 4 subunits mediate extrasynaptic inhibition in thalamus and dentate gyrus and the action of gaboxadol.

Authors:  D Chandra; F Jia; J Liang; Z Peng; A Suryanarayanan; D F Werner; I Spigelman; C R Houser; R W Olsen; N L Harrison; G E Homanics
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-27       Impact factor: 11.205

6.  Limiting activity at beta1-subunit-containing GABAA receptor subtypes reduces ataxia.

Authors:  Kelvin W Gee; Minhtam B Tran; Derk J Hogenkamp; Timothy B Johnstone; Rudy E Bagnera; Ryan F Yoshimura; Jin-Cheng Huang; James D Belluzzi; Edward R Whittemore
Journal:  J Pharmacol Exp Ther       Date:  2009-11-25       Impact factor: 4.030

7.  Blockade of the discriminative stimulus effects of gamma-hydroxybutyric acid (GHB) by the GHB receptor antagonist NCS-382.

Authors:  G Colombo; R Agabio; J Bourguignon; F Fadda; C Lobina; M Maitre; R Reali; M Schmitt; G L Gessa
Journal:  Physiol Behav       Date:  1995-09

Review 8.  Behavioral analyses of GHB: receptor mechanisms.

Authors:  Lawrence P Carter; Wouter Koek; Charles P France
Journal:  Pharmacol Ther       Date:  2008-10-29       Impact factor: 12.310

9.  High affinity binding sites for gamma-hydroxybutyric acid in rat brain.

Authors:  J Benavides; J F Rumigny; J J Bourguignon; C Cash; C G Wermuth; P Mandel; G Vincendon; M Maitre
Journal:  Life Sci       Date:  1982-03-15       Impact factor: 5.037

Review 10.  Extrasynaptic GABAA receptors: form, pharmacology, and function.

Authors:  Delia Belelli; Neil L Harrison; Jamie Maguire; Robert L Macdonald; Matthew C Walker; David W Cope
Journal:  J Neurosci       Date:  2009-10-14       Impact factor: 6.167

View more
  35 in total

Review 1.  [Not all drugs are the same].

Authors:  L S Weilemann
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-08-24       Impact factor: 0.840

2.  Gamma-Hydroxybutyrate (GHB) Content in Hair Samples Correlates Negatively with Age in Succinic Semialdehyde Dehydrogenase Deficiency.

Authors:  S S Johansen; X Wang; D Sejer Pedersen; P L Pearl; J-B Roullet; G R Ainslie; K R Vogel; K M Gibson
Journal:  JIMD Rep       Date:  2017-02-18

3.  Extrasynaptic site of action for γ-hydroxybutyrate.

Authors:  S J Enna
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-31       Impact factor: 11.205

4.  α1F64 Residue at GABA(A) receptor binding site is involved in gating by influencing the receptor flipping transitions.

Authors:  Marcin Szczot; Magdalena Kisiel; Marta M Czyzewska; Jerzy W Mozrzymas
Journal:  J Neurosci       Date:  2014-02-26       Impact factor: 6.167

5.  Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers.

Authors:  Nathalie Pross; Alain Patat; Philippe Vivet; Michelle Bidaut; Nicolas Fauchoux
Journal:  Br J Clin Pharmacol       Date:  2015-08-11       Impact factor: 4.335

6.  New synthesis and tritium labeling of a selective ligand for studying high-affinity γ-hydroxybutyrate (GHB) binding sites.

Authors:  Stine B Vogensen; Aleš Marek; Tina Bay; Petrine Wellendorph; Jan Kehler; Christoffer Bundgaard; Bente Frølund; Martin H F Pedersen; Rasmus P Clausen
Journal:  J Med Chem       Date:  2013-10-04       Impact factor: 7.446

7.  Toxicologic/transport properties of NCS-382, a γ-hydroxybutyrate (GHB) receptor ligand, in neuronal and epithelial cells: Therapeutic implications for SSADH deficiency, a GABA metabolic disorder.

Authors:  K R Vogel; G R Ainslie; A McConnell; J-B Roullet; K M Gibson
Journal:  Toxicol In Vitro       Date:  2017-10-12       Impact factor: 3.500

Review 8.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

9.  The orthosteric GABAA receptor ligand Thio-4-PIOL displays distinctly different functional properties at synaptic and extrasynaptic receptors.

Authors:  K Hoestgaard-Jensen; R M O'Connor; N O Dalby; C Simonsen; B C Finger; A Golubeva; H Hammer; M L Bergmann; U Kristiansen; P Krogsgaard-Larsen; H Bräuner-Osborne; B Ebert; B Frølund; J F Cryan; A A Jensen
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

10.  GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Tsui-Ming Chen; Andrew K Leung; Jonathan P Wisor; Akihiro Yamanaka; Thomas S Kilduff
Journal:  J Neurosci       Date:  2014-05-07       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.